These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16791626)

  • 21. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
    Berry WR
    Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.
    Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; De Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
    BJU Int; 2007 Oct; 100(4):775-9. PubMed ID: 17535276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.
    Shimazui T; Kawai K; Miyanaga N; Kojima T; Sekido N; Hinotsu S; Oikawa T; Joraku A; Akaza H
    Jpn J Clin Oncol; 2007 Aug; 37(8):603-8. PubMed ID: 17673473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
    Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
    J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
    Lin AM; Ryan CJ; Small EJ
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
    Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
    Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
    Naito S; Tsukamoto T; Koga H; Harabayashi T; Sumiyoshi Y; Hoshi S; Akaza H
    Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
    Kikuno N; Urakami S; Nakamura S; Hiraoka T; Hyuga T; Arichi N; Wake K; Sumura M; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
    Eur Urol; 2007 May; 51(5):1252-8. PubMed ID: 17208356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
    Oh WK; Manola J; Babcic V; Harnam N; Kantoff PW
    Urology; 2006 Jun; 67(6):1235-40. PubMed ID: 16765185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.
    Mountzios I; Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Karadimou A; Tsiatas M; Papadimitriou C; Bamias A; Dimopoulos MA
    Urology; 2011 Mar; 77(3):682-7. PubMed ID: 21256546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
    Dawson NA; Halabi S; Ou SS; Biggs DD; Kessinger A; Vogelzang N; Clamon GH; Nanus DM; Kelly WK; Small EJ;
    Clin Genitourin Cancer; 2008 Sep; 6(2):110-6. PubMed ID: 18824434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
    Goodin S; Medina P; Capanna T; Shih WJ; Abraham S; Winnie J; Doyle-Lindrud S; Todd M; DiPaola RS
    J Clin Oncol; 2005 May; 23(15):3352-7. PubMed ID: 15738531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.
    Seruga B; Tannock IF
    Nat Clin Pract Oncol; 2008 Oct; 5(10):574-6. PubMed ID: 18628739
    [No Abstract]   [Full Text] [Related]  

  • 38. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current strategies of intermittent hormone therapy in prostate cancer].
    Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
    Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.